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Abstract
Background: the prevalence of individuals with cognitive decline is increasing since the number
of elderly adults is growing considerably. The literature provides promising results on the beneficial
effect of exercise and vitamin supplementation on cognitive function both in cognitively healthy as
well as in the demented elderly.
Methods/Design: the design is a two-by-two factorial randomised controlled trial. The study
population consists of independently living elderly, between 70 and 80 years old, with mild cognitive
impairment (MCI). In the RCT the effect of two interventions, a walking program and vitamin
supplementation, is examined. The walking program (WP) is a group-based program aimed at
improving cardiovascular endurance; frequency two lessons a week; lesson duration one hour;
program duration one year. Non-walking groups receive a placebo activity program (PAP) (i.e. low
intensive non-aerobic group exercises, like stretching) with the same frequency, lesson and
program duration. Vitamin supplementation consists of a single daily vitamin supplement containing
50 mg B6, 5 mg folic acid and 0,4 mg B12 for one year. Subjects not receiving vitamin supplements
are daily taking an identically looking placebo pill, also for a year. Participants are randomised to
four groups 1) WP and vitamin supplements; 2) WP and placebo supplements; 3) PAP and vitamin
supplements; 4) PAP and placebo supplements. Primary outcome measures are measures of
cognitive function. Secondary outcomes include psychosocial wellbeing, physical activity,
cardiovascular endurance and blood vitamin levels.
Discussion: no large intervention study has been conducted yet on the effect of physical activity
and vitamin supplementation in a population-based sample of adults with MCI. The objective of the
present article is to describe the design of a randomised controlled trial examining the effect of a
walking program and vitamin B supplementation on the rate of cognitive decline in older adults with
MCI.
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Because cognitive function decreases with age and the
number of elderly is increasing worldwide, the number of
older adults with cognitive dysfunction is also increasing.
Since no cure for dementia is available yet, this process
will put a considerable burden on the healthcare system
and on society in general. Therefore, for both individuals
and society it is necessary to develop strategies for main-
taining physical, mental and cognitive wellbeing of the
aging population.
In this manuscript the design is described of a randomised
controlled trial on the effect of a moderate intensive walk-
ing program and vitamin B-supplementation in an older
population with mild cognitive impairment (MCI)
recruited from the general population.
Mild cognitive impairment
MCI refers to a stage in which persons experience memory
loss to a greater extent than one would expect for age, but
do not yet meet currently accepted criteria for clinically
probable dementia or Alzheimer Disease (AD) [1]. Preva-
lence of MCI in adults with a mean age of 75 years is three
to four percent [2,3]. Compared to elderly with normal
cognitive function, adults with MCI have an increased risk
to develop dementia or AD [1,4,5]. Progression rates to
dementia and AD for adults with MCI vary from 6 % to 25
% per year, depending on the criteria for MCI [6]. The rate
of progression to AD in adults with MCI according to the
criteria of Petersen et al. is 12%, compared with a rate of
1–2% per year in control subjects [4].
As the stage of MCI may be the optimum stage at which to
intervene with preventive therapies [7,8], new treatments
to prevent development of AD are targeting elderly with
MCI [7].
Physical activity
The hypothesis of physical activity positively influencing
cognition is supported by observational studies that
found higher levels of physical activity were associated
with a reduced risk of cognitive decline and dementia in
healthy elderly [9-13].
Positive effects of exercise programs on cognitive function
have been found also in various trials among cognitively
healthy elderly [14-17]. Programs lasted from two months
[14] to one year [16], frequency and intensity differed per
program. Improvements in memory [14], immediate
recall [16,17] and tasks requiring executive control proc-
esses [15] have been reported.
Also a number of reviews and a meta-analysis have been
conducted on the effects of physical exercise on cognition
in healthy elderly [18-20]. Exercise seems to have a posi-
tive effect on cognitive functioning, but findings in the
individual studies are contradictory and the effect size can
be considered small. However, two recently published
meta-analyses reported moderate effect size values,
around 0.5, from group based aerobic fitness training on
cognitive performance in healthy elderly [21] and from
various types of exercise programs in elderly with demen-
tia [22].
Besides an effect on cognitive function, Biddle and
Faulkner [23] concluded in their review that clear benefi-
cial effects from physical activity are evident for psychoso-
cial wellbeing in older adults.
Possible pathways for the effect of physical activity on cog-
nitive function are increased blood flow to the brain,
improved vascularisation, improved neurogenesis,
increased neurotransmitter availability and better neural
efficiency[24,25].
Vitamin B supplementation
Cognitive function may benefit as well from supplemen-
tation with folic acid, vitamin B12 and vitamin B6 (FA/
B12/B6 respectively). Metabolic FA/B12/B6 deficiencies
are relatively common in older adults [26,27], even in the
presence of normal serum vitamin levels [28]. Low levels
of FA/B12/B6 seem to be associated with poorer cognitive
function [29-31]. Besides a reverse effect on cognitive
function, FA/B12/B6 deficiencies result in elevated levels
of the amino acid homocysteine [32], as these vitamins
are linked to the metabolism of homocysteine.
An elevated homocysteine level has been found to be a
strong independent risk factor for the development of
dementia and AD as well [33]. Negative associations have
been found between increased homocysteine levels and
global cognitive performance [34-36], memory [37,38],
psychomotor speed [38,39] and spatial copying skills
[29], even in the generally normal accepted range of
homocysteine (25th–75th percentile (7.6–11.3 µmol/L))
[38]. Above a threshold of approximately 14 µmol/L sig-
nificantly lower cognitive performances were observed as
well [39-41].
Supplementation with vitamin B reduces the homo-
cysteine level [42,43]. Supplementation with folic acid
after standardisation for pre-treatment blood concentra-
tions of homocysteine and folic acid resulted in an
approximate decrease of homocysteine level of 25 per-
cent. Vitamin B12 produced an additional 7 percent
reduction [44].
Few experimental studies have been conducted on the
effect of B-vitamin supplementation in enhancing cogni-
tive performance in older adults. Bryan and CalvaresiPage 2 of 9
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formance after 35 days of (FA/B12/B6) supplementation
in healthy middle aged and older women. Fioravanti et al.
[46] concluded in a double blind controlled trial that 15
mg folic acid daily for 60 days given to older adults with
global impairment in all components of memory func-
tioning (i.e. a more seriously decline than MCI), appeared
to improve their memory. Vitamin B12 injections of dif-
ferent doses improved memory in elderly with B12 defi-
ciency and without cognitive impairment in a single blind
controlled trial [47]. Finally, cognitive performance in
elderly with elevated plasma homocysteine and a diagno-
sis of mild to moderate dementia improved after com-
bined supplementation of 5 mg folic acid and 1 mg
vitamin B12 daily for two months [48]. Unfortunately
most of these trials included few subjects and, therefore,
results have to be interpreted with care.
Calvaresi and Bryan (2001) hypothesised that FA/B12/B6
may affect cognitive performance via two interrelated
ways: a direct and possibly acute influence via hypometh-
ylation and a longer term influence on homocysteine lev-
els resulting in structural vascular changes in the brain
[49].
No clinical trials are yet available that have examined the
effect of physical activity and vitamin supplementation in
a population based sample of adults with MCI. Therefore,
the main objective of project FACT (Folate physical Activ-
ity Cognition Trial) is to examine the effect of a walking
program and vitamin B supplementation on the rate of
cognitive decline in adults aged 70 to 80 years with mild
cognitive impairment in a randomised controlled trial.
Also effects of both interventions on psychosocial wellbe-
ing, habitual physical activity and cardiovascular endur-
ance will be examined.
Methods/Design
Study design
The study is designed as a randomised, placebo controlled
intervention trial, based on a two-by-two factorial design.
The design is presented in figure 1. It is assumed that the
effect of both interventions is independent. The study pro-
tocol was approved by the VU University Medical Center
medical ethics committee.
Setting
This study is carried out in Alkmaar, a medium sized city
in The Netherlands, with approximately 100,000 inhabit-
ants.
Study population
This study is targeted at a population based sample meet-
ing the criteria for mild cognitive impairment: i.e. mem-
ory complaint, memory impairment, normal general
cognitive function, normal activities of daily living and
not demented [4]. In the recruitment procedure the crite-
ria for MCI are checked in both a questionnaire and a tel-
ephone interview. Other inclusion criteria for
participating in the trial are checked for only in the ques-
tionnaire (table 1).
Questionnaire
To recruit participants a questionnaire is sent to all inde-
pendently living elderly in Alkmaar, with an age between
70 and 80 years old. Their addresses are provided by the
register of population of the municipality of Alkmaar. Pri-
mary aim of the questionnaire is to check two criteria for
MCI, memory complaints and normal activities of daily
living. Memory complaints are assessed by the question
'do you have memory complaints' and the cognition scale
of Strawbridge [50]. Activities of daily living (ADL) are
assessed using the Groningen Activity Restriction Scale
(GARS) [51]. Secondary aims are to collect demographic
variables and to check the other inclusion criteria for trial
participation. Together with filling in the questionnaire,
participants are requested to give informed consent.
Design of the RCT (WP = walking program, PAP = placebo activity program)Figure 1
Design of the RCT (WP = walking program, PAP = placebo 
activity program).Page 3 of 9
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Respondents fulfilling the inclusion criteria are being
phoned for a telephone interview for cognitive status. In
this telephone interview a brief measure of general cogni-
tive function (TICS) [52] and a modified version of the
ten word learning test [53] are administered. Adults with
a score of 20 or more on the TICS, corresponding to nor-
mal cognitive function, and with a performance on the
delayed recall score on the ten word learning test of less
than five are considered as having mild cognitive impair-
ment. A delayed recall score of five or less corresponds
with one standard deviation below normal performance
[54]. Participants fulfilling these criteria receive an invita-
tion letter for a baseline measurement during a personal
interview.
Sample size
The aim is to enrol 170 participants. A power analysis has
been executed on the auditory verbal learning test. To be
able to detect a difference of 5 points on direct recall (see
2.9.1) 34 participants per group are required and thus 136
participants in total. These numbers are based on a power
of 80% and a significance level of 0.05. We expect a drop-
out rate of 25 percent, based on experiences with compa-
rable research. Therefore, 170 participants will be
recruited.
Randomization
To ensure an equal distribution of physically inactive and
active subjects in each group, participants are classified as
active or inactive on the basis of their activity level as
measured using the LASA physical activity questionnaire
[55]. Adults with an activity level exceeding the median
level of the whole group are classified as active and adults
below this level are classified as inactive. Active and inac-
tive subjects are allocated separately and randomly to one
of the four intervention groups using the option 'random
sample of cases' in the statistical computer program SPSS.
Blinding
The study is conducted double blind. The key of coding
for FA/B12/B6 supplementation is only known to the
manufacturer of the supplements, who will decode the
key after data-analysis. All outcome measures on cogni-
tion and wellbeing are assessed by independent examin-
ers unaware of group allocation.
Co-interventions and compliance
During the intervention period co-interventions are dis-
couraged by asking adults not to start an exercise program
or vitamin supplementation while being a participant.
Both vitamin supplementation and physical activity level
will be asked for at baseline and after 6 and 12 months.
Compliance with the walking program is assessed as the
percentage of attended lessons. Compliance with the vita-
min supplementation is verified by pill counts and deter-
mining blood vitamin levels.
Intervention
Walking program and placebo activity program
Walking program (WP)
The walking program is based on 'Sportive Walking', an
existing aerobic exercise program [56]. Each lesson con-
sists of a warming-up, moderate intensity walking exer-
cises and a cooling-down. Lessons for project FACT are
developed by two certified walking instructors and
recorded in a manual. The duration and intensity of the
WP are increased gradually during the program by increas-
ing the total walking time and distance. The WP is devel-
oped in such a way that all subjects can perform the
walking exercises at their own level, but still walk in a
Table 1: Inclusion criteria
Criteria for MCI (1–4) and other inclusion criteria for the RCT (5–11)
1. self reported memory complaints (answer yes to question 'do you have memory complaints', or at least twice sometimes at cognition scale of 
Strawbridge)
2. no report of disability in activities of daily living on GARS-scale, except on the item 'taking care of feet and toe nails'
3. objective memory impairment; 10 wlt delayed recall ≤5 + percentage savings ≤ 100
4. normal general cognitive functioning/absence of dementia; TICS ≥ 19
5. being able to moderate intensive physical activity without making use of walking devices, e.g. rollator, of walking frame
6. not using vitamin supplements/vitamin injections/drinks with dose of vitamin B6, B11 or B12 comparable to vitamin supplement given in 
intervention
7. not suffering from epilepsy, multiple sclerosis, Parkinson's disease, kidney disorder requiring haemodialysis, psychiatric impairment
8. not suffering from depression as measured by the Geriatric Depression Scale (cut off ≤ 5)
9. not using medication for rheumatoid arthritis or psoriasis interfering with vitamin supplement
10. no alcohol abuse (men < 21 consumptions a week, women < 15 consumptions a week)
11. not currently living in or on a waiting list for a nursing homePage 4 of 9
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routes with the same beginning and end.
Lessons are being given outdoors in municipal parks in
Alkmaar. Only when it is slippery due to snow or freezing
rain the lessons will be cancelled.
Placebo activity program (PAP)
The PAP is developed by four experienced exercise instruc-
tors. The program consists of an introduction, low inten-
sity non-aerobic group exercises such as light range of
motion movements and stretching, and a closing. Lessons
are divided into five themes: relaxation, activities of daily
living, balance, flexibility, posture, and a combination of
all. For each theme three lessons are developed and the
entire series of 18 lessons is repeated during the interven-
tion period. The program takes place in a community
center.
Both programs are group-based and last one year, the fre-
quency is twice a week and lesson duration is 60 minutes.
The intensity is checked by heart rate monitors (Polar,
Vantage NV) and Borg scales in a sub sample of the popu-
lation during one lesson at baseline and after twelve
months and during two lessons at six months follow up.
To provide an intervention class in or near the subjects'
own neighbourhood, eight classes for the walking pro-
gram and eight classes for the placebo activity program are
started in four districts. These classes are organized espe-
cially for the study and only study participants are able to
join. All exercise classes are supervised by qualified
instructors. In total four trained walking instructors for
the walking program and four exercise instructors for the
placebo activity program are hired for the study. The
number of participants in a group is 19 at the most.
Folic acid/vitamin B12/vitamin B6 supplementation
Subjects in the intervention group are asked to take daily
one pill containing 5 mg folic acid, 0.4 mg vitamin B12
and 50 mg B6 during a year. Subjects who do not get FA/
B12/B6 supplementation receive an identically looking
placebo pill. The pills are packed in blister packs contain-
ing seven pills that are labelled for each day of the week.
Measurements
All outcome measures are collected at baseline and after 6
and 12 months. The primary outcome measures are meas-
ures of cognitive function. Secondary measures are meas-
ures of psychosocial health, habitual physical activity and
cardiovascular endurance. Also physical measures are per-
formed. Most cognitive and psychosocial data are gath-
ered during a standardized interview. These face-to-face
interviews are conducted in the Medical Center Alkmaar
and last a maximum of 90 minutes, including a short
break.
Primary outcome measures
Five interviewer administered cognitive outcome meas-
ures are chosen to assess different aspects of cognitive
functioning. Only the informant questionnaire is self
administered.
Mini Mental State Examination (MMSE)
general cognitive function is measured with the MMSE.
The MMSE consists of 11 questions concerning orienta-
tion, registration, attention and calculation, recall and
language. The maximum score is 30 and a score below 24
is considered abnormal for dementia screening [57].
Auditory Verbal Learning Test (AVLT)
a Dutch version of the AVLT is used. This is a measure of
memory in which direct and delayed recall are assessed.
During the test a list of 15 monosyllabic words is read
aloud by the examiner for 5 times. After each trial the sub-
ject is asked to repeat the words he or she remembers.
After fifteen minutes with other questions, delayed recall
is assessed by asking the participant which words he or
she still remembers [58]. At baseline and after 12 months
the same version of the test is administered and after 6
months a parallel version with 15 different words is
administered.
Letter fluency test (LFT)
this is a measure of expressive language. If language is
intact, the LFT is also a measure of executive functioning.
The subject is given a letter and is asked to name words
beginning with the particular letter in one minute. In one
administration of the test three letters are given. At the 6
and 12 months follow up measurements parallel versions
with different letters are administered [59].
Digit symbol substitution test (DSST)
This is a measure of attention, perceptual speed, motor
speed, visual scanning and memory. The subject is given a
piece of paper with nine symbols corresponding with nine
digits. Next on this piece of paper are three rows of digits
with empty spaces below them. The subject is asked to fill
in as many corresponding symbols as possible in 90 sec-
onds [60].
Abridged Stroop colour word test (SCWT-A)
this is a measure of complex processing. The SCWT-A con-
sist of three tasks; 1) word reading, 8 rows of 5 written col-
ours; 2) colour naming, naming the colours of 8 rows of
5 red, green, blue or yellow coloured rectangles; 3) com-
bination task, the words red, green, blue or yellow have
been printed in a different colour of ink, the subject is
asked to name the colour of the ink [61].Page 5 of 9
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in this questionnaire a significant other of the participant
is asked to answer 16 questions about changes in the par-
ticipant's cognitive function during the last ten years
[62,63].
Secondary measures
Three interviewer administered questionnaires are used to
complete the picture of psychosocial health. Only the ger-
iatric depression scale is self administered.
psychosocial wellbeing
Short Form 12 (SF-12)
The SF-12 is a measure of health status consisting of
twelve items measuring eight concepts of both physical
and mental health. The physical and mental component
summary scales are scored using norm-based methods
[64].
Dementia Quality of Life (D-QoL)
The D-QoL is a 29 item measure especially developed for
elderly with cognitive decline and dementia. Five
domains are measured: self esteem, positive affect/
humour, negative affect, feelings of belonging and sense
of aesthetics. The response scale is a five point scale with
higher score indicating better quality of life [65].
Euro Quality of Life (Euro-QoL)
The Euro-QoL questionnaire is a standardized measure
for general health status measuring five dimensions:
mobility, self care, usual activities, pain/discomfort and
anxiety/depression. The participant is asked to choose
from three answer levels for each dimension. By compos-
ing a five digit number consisting of the three answer lev-
els on the five dimensions participants can be classified
into one of 243 defined health states [66].
Geriatric Depression Scale (GDS)
The GDS is a self administered depression scale for the
elderly. The short version is used in which participants are
asked to report how they felt the last week by answering
15 yes/no questions. The maximum score is 15 and a
score over five points is suggestive of depression [67].
physical activity and cardiovascular endurance
Physical activity level
During the face-to-face interview the LASA physical activ-
ity questionnaire [55] is administered to determine the
physical activity level of the participants. Participants are
interviewed about their physical activities during the last
two weeks by asking questions about the frequency and
duration of different activities (e.g. housekeeping, sports
activities, cycling, gardening). These answers are con-
verted to an overall physical activity score expressed in
minutes of physical activity per day.
Accelerometer
A random sample of subjects of each of the four interven-
tion groups is asked to wear an accelerometer (ActiGraph,
activity monitor) for three days. Data will be used to com-
pare the level of activity in participants in the walking pro-
gram and in the placebo activity group.
Cardiovascular endurance
this is assessed in a sports hall using the walking test of the
Groningen Fitness test for the elderly [68]. This is a sub-
maximal test for aerobic endurance in which adults walk
distances of 16.6 meters between pylons in a large rectan-
gle of 16.6 by 8.3 meters. For every walked distance a score
of one point is given. To increase their score, adults have
to be within a three meter distance of the next pylon
before a signal sounds. A double signal sounds when
walking speed is increased. Walking speed is increased
every three minutes with one kilometre starting with a
walking speed of four kilometres per hour to a maximum
walking speed of seven kilometres per hour. If they fail
twice to reach the next pylon in time, the test is finished
for that particular participant. The maximum score of 66
points corresponds to a total walking distance of 1.1 kilo-
metres.
Physical measures
Anthropometric measurements
During the break in the face-to-face interview body height
and body weight are measured for calculating body mass
index (kg/m2).
Blood pressure
Blood pressure is measured electronically (Omron M5-1)
after five minutes of rest during the face-to-face interview.
Participants with a diastolic blood pressure exceeding 95
and a systolic blood pressure exceeding 160 are offered to
have their blood pressure measured again by a geriatri-
cian. If hypertension is diagnosed, the participant will be
treated.
Blood vitamin levels
non-fasting blood samples are taken at the laboratory of
the Medical Center Alkmaar to determine blood vitamin
levels.
Plasma concentrations of homocysteine, serum folate lev-
els and vitamin B12 levels in serum are determined by a
competitive immunoassay using direct chemiluminescent
technology. (ADVIA CENTAUR, Bayer Corporation, Tarry-
town, USA).
For determination of red cell folate hemolysates are pre-
pared out of EDTA plasma and ascorbic acid. Folate in
erythrocytes is determined in the hemolysate by a compet-
itive immunoassay using direct chemiluminescent tech-Page 6 of 9
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Tarrytown, USA). According to the manufactures instruc-
tions folate in erythrocytes is calculated using the follow-
ing algorithm: folate in hemolysate × 21 minus folate in
serum × ((100 – hematocrit)/(hematocrit * 100)).
Vitamin B6 in plasma is determined by high performance
liquid chromatography with fluorescence detection using
Chrompack Lichrosorb RP-18 columns (Varian Inc., Palo
Alto, USA) and the Jasco HPLC system (Jasco Benelux,
Maarssen, The Netherlands).
Statistical analyses
Analyses will focus upon estimating the effect of both
interventions on four domains: 1) cognitive functioning;
2) psychosocial wellbeing; 3) habitual physical activity
and cardiovascular endurance; 4) blood vitamin levels
and homocysteine. The effect of physical activity and FA/
B12/B6 supplementation will be examined independ-
ently from each other as we do not expect an interaction
between these interventions.
Before analyses are performed there will be a check-up on
the comparability at baseline of the intervention groups.
If necessary, analyses will be adjusted for baseline differ-
ences. Subsequently, the data set will be analysed accord-
ing to the intention to treat and according to the intention
per protocol principle.
The difference between the walking program and the pla-
cebo activity program, and between the verum and pla-
cebo supplements will be assessed using linear regression.
The dependent variables will be values after 6 and 12
months in the four before mentioned domains. Both
interventions will be independent variables. Besides,
regression analyses will be adjusted for baseline values
and possibly confounding covariates such as gender and
age. Also effect modification by sex will be investigated
using interaction terms.
Discussion
The literature provides promising results on the beneficial
effect of exercise and folic acid/vitamin B12/vitamin B6
supplementation on cognitive function and wellbeing
both in cognitive healthy as well as in the demented eld-
erly. However, to our knowledge, no large intervention
study has been conducted yet on the effect of these inter-
ventions on cognitive decline in subjects with MCI. In the
present study, the effects on cognitive function and psy-
chosocial health will be examined in a population sample
of community dwelling elderly adults aged 70 to 80 years.
A factorial design is used and it is assumed that the inter-
ventions have an independent effect. We hypothesize that
both exercise and FA/B12/B6 supplementation benefi-
cially influence cognitive function and psychosocial
health in this particular group of elderly.
The results of this trial will provide clinicians in the field
of aging with more knowledge about treatment of older
persons with cognitive decline. If proven effective, exercise
and vitamin supplementation are an additional interven-
tion method for this target group.
Implementation of the walking program in the Nether-
lands is relatively easy, since infrastructure for group
based exercise programs for the elderly already exists.
Vitamin supplementation is easy to implement as well.
The most difficult aspect might be long term compliance
in case of severe cognitive decline. However, compliance
can be sustained by providing methods to remember tak-
ing the vitamin supplements.
An additional important advantage of both interventions
is that involvement of the clinician is limited to prescrib-
ing exercise and vitamin supplementation and possibly to
evaluate compliance at future medical check-ups.
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